Laser Diffraction vs DLS — PatSnap Eureka
Laser Diffraction vs Dynamic Light Scattering in Pharma Manufacturing
Two powerful techniques, fundamentally different physics. Understanding when to use laser diffraction versus dynamic light scattering is critical for accurate particle size characterisation, regulatory compliance, and robust pharmaceutical formulation development.
Different Physics, Different Answers
Laser diffraction (LD) operates on ISO-standardised Mie scattering theory. When a coherent laser beam strikes a particle, light scatters at angles that are inversely proportional to particle size. A multi-element detector array captures this angular scattering pattern, and mathematical inversion yields a volume-weighted particle size distribution. For larger particles, the Fraunhofer approximation simplifies the computation without meaningful loss of accuracy.
Dynamic light scattering (DLS) measures something fundamentally different: time. Specifically, it tracks the time-dependent fluctuations in scattered laser light caused by the Brownian motion of particles in suspension. Smaller particles diffuse faster and produce more rapid intensity fluctuations. The autocorrelation function of these fluctuations is analysed to extract a translational diffusion coefficient, which is then converted to hydrodynamic diameter via the Stokes-Einstein equation. DLS also reports the polydispersity index (PDI), a critical quality attribute for nanomedicine formulations.
The result is that LD reports a volume-weighted size distribution while DLS reports an intensity-weighted hydrodynamic diameter — two different physical quantities that are not directly comparable even when measuring the same material. Understanding this distinction is essential for pharmaceutical R&D teams selecting the right method for regulatory submissions.
Matching Technique to Formulation Type
The choice between laser diffraction and DLS is largely determined by the physical nature of the drug product and the size regime of the particles being characterised.
Dry Powders & Inhalation Products
Laser diffraction is the method of choice for dry powder inhalation (DPI) formulations, where aerodynamic particle size in the 1–10 µm range determines lung deposition. The technique handles both wet dispersion and dry dispersion modes, enabling measurement of APIs, excipients, and final blends. It is also the standard for granulation monitoring, milling endpoint determination, and blend uniformity assessment in solid dosage manufacturing. Regulatory guidance from the EMA and FDA specifically references LD for orally inhaled products.
Best for: DPI, granules, tablets, oral solidsNanosuspensions, Liposomes & Biologics
DLS is indispensable for characterising nanoparticulate drug delivery systems — liposomes, polymeric nanoparticles, solid lipid nanoparticles, and protein-based biologics. Its sensitivity to particles below 1 µm and its ability to detect trace aggregates make it a critical tool for biologic stability studies and nanomedicine quality control. The PDI output from DLS is a regulatory expectation for liposomal submissions. ICH Q1B photostability and ICH Q6B specifications for biologics both require particle characterisation data that DLS provides.
Best for: liposomes, nanoparticles, mAbs, ADCsEmulsions & Suspensions (Coarser Range)
For parenteral emulsions and ophthalmic suspensions where droplet or particle size spans the 0.5–100 µm range, laser diffraction provides a comprehensive volume-weighted distribution that captures the full breadth of the population. This is particularly valuable for detecting oversized particles or globules that could pose safety risks in injectable emulsions — a concern specifically addressed in USP <729> for injectable emulsions.
Best for: parenteral emulsions, ophthalmic suspensionsProtein Aggregation & Stability Monitoring
In biologic drug development, DLS serves as an early-warning tool for protein aggregation — a critical quality attribute linked to immunogenicity risk. Its sensitivity to trace quantities of large aggregates (which scatter disproportionately more light) makes it far more sensitive than LD for detecting sub-visible particle formation during formulation screening, freeze-thaw cycling, and accelerated stability studies. Many life sciences R&D teams run DLS as a routine release and stability test for monoclonal antibodies.
Best for: mAbs, fusion proteins, vaccine antigensTechnique Fit by Formulation & Size Domain
Visual comparison of how laser diffraction and dynamic light scattering perform across key pharmaceutical formulation categories and particle size regimes.
Application Suitability by Formulation Type
Relative suitability of each technique across five pharmaceutical formulation categories — higher indicates stronger fit for routine QC and regulatory submission.
Size Range Coverage by Technique
Proportion of the pharmaceutical particle size spectrum (1 nm–3,500 µm) accessible by each technique — laser diffraction covers ~85% of the total log-scale range; DLS covers ~40%.
Laser Diffraction vs DLS: Key Technical Parameters
A direct comparison of the most important technical and regulatory parameters for pharmaceutical analytical method selection.
| Parameter | Laser Diffraction | Dynamic Light Scattering |
|---|---|---|
| Measurement Principle | Mie scattering / angular light scatter pattern | Brownian motion / autocorrelation of intensity fluctuations |
| Size Range | 0.1 µm – 3,500 µm Broader | 1 nm – ~1 µm |
| Output Metric | Volume-weighted size distribution (D10, D50, D90, span) | Intensity-weighted hydrodynamic diameter (Z-average) + PDI |
| Sample State | Wet dispersion or dry dispersion | Liquid suspension only |
| Aggregate Detection | Moderate — volume weighting can mask trace aggregates | Excellent Preferred — intensity weighting amplifies large particles |
| Pharmacopoeial Standard | USP <429>, Ph. Eur. 2.9.31, ISO 13320 | USP <429>, Ph. Eur. 2.9.31, ISO 22412 |
| Primary Pharma Use | Dry powders, inhalation, granulation, oral solids | Liposomes, nanoparticles, biologics, protein stability |
Search analytical method patents by technique and formulation
PatSnap Eureka covers 120+ countries of patent data to map the competitive landscape.
Pharmacopoeial Standards & ICH Alignment
Both techniques are recognised in major pharmacopoeias, but the applicable chapters and validation requirements differ. Selecting the wrong method can delay regulatory submissions.
USP <429> and Ph. Eur. 2.9.31
Both laser diffraction and DLS are addressed under USP <429> (Light Diffraction Measurement of Particle Size) and its European equivalent Ph. Eur. 2.9.31. The chapters specify system suitability requirements, reference material standards, and acceptance criteria for method validation. ISO 13320 governs LD specifically, while ISO 22412 governs DLS. Submissions must declare which standard was followed.
ICH Q4A Harmonisation Framework
The ICH Q4A framework provides the overarching structure for analytical method harmonisation across FDA, EMA, and PMDA jurisdictions. Both techniques are recognised within this framework, but method validation requirements under ICH Q2(R1) — including specificity, linearity, range, precision, and accuracy — apply fully to both. The harmonisation framework does not prescribe which technique to use; that decision rests on the physical nature of the drug product.
Using Both Techniques Together: An Orthogonal Approach
The most sophisticated pharmaceutical development programmes do not choose between laser diffraction and DLS — they deploy both as part of an orthogonal characterisation strategy. This approach is increasingly expected by regulators for complex drug products, particularly those involving nanomedicine or novel delivery systems.
A typical workflow for a liposomal drug product might use DLS during early formulation screening to optimise vesicle size and PDI, then employ laser diffraction to characterise the bulk powder intermediate if a lyophilised form is being developed, and return to DLS for reconstituted product release testing and stability monitoring. The IP analytics landscape shows growing patent activity around multi-technique characterisation platforms that integrate both measurement modalities.
For in-process control during manufacturing, laser diffraction offers a practical advantage: it can be configured in-line or at-line for continuous particle size monitoring during wet granulation, milling, or crystallisation — applications where DLS is impractical due to concentration and optical clarity requirements. PatSnap customers in pharmaceutical manufacturing use Eureka to track innovation in process analytical technology (PAT) applications of both techniques.
The overlap region between approximately 100 nm and 1 µm is where both techniques can measure the same material, enabling cross-validation. Discrepancies in this region — for example, a DLS Z-average that differs significantly from a laser diffraction D50 — are analytically informative: they reveal information about particle shape, aggregation state, or polydispersity that neither technique alone would expose. Developers seeking to build robust analytical control strategies can explore the relevant patent landscape via PatSnap Eureka.
Laser Diffraction vs DLS — key questions answered
Laser diffraction covers a broad dynamic range typically from around 0.1 µm to several millimetres, making it well-suited for dry powders, granules, and larger particulate systems. Dynamic light scattering excels in the sub-micron and nanometre regime, typically from approximately 1 nm to 1 µm, making it the preferred technique for nanoparticles, liposomes, protein aggregates, and colloidal dispersions.
Dynamic light scattering is the preferred technique for nanosuspensions and liposomal drug products because it operates in the nanometre size range where these formulations exist. DLS measures Brownian motion via the Stokes-Einstein equation to derive hydrodynamic diameter, and also reports the polydispersity index (PDI), which is a critical quality attribute for liposomes and nanoparticle drug carriers.
Laser diffraction operates on Mie scattering theory (and Fraunhofer approximation for larger particles). When a laser beam strikes particles, light is scattered at angles inversely related to particle size. A detector array captures the angular scattering pattern, and mathematical inversion yields a volume-weighted particle size distribution. The technique is fast, reproducible, and applicable across a wide size range.
Dynamic light scattering measures the time-dependent fluctuations in scattered laser light caused by Brownian motion of particles in suspension. The autocorrelation function of these fluctuations is analysed to extract a diffusion coefficient, which is then converted to hydrodynamic diameter via the Stokes-Einstein equation. The technique is highly sensitive to small particles and detects aggregates at trace levels.
Laser diffraction is governed by USP <429>, Ph. Eur. 2.9.31, and ISO 13320. Dynamic light scattering is governed by USP <429> (for nanoparticles), Ph. Eur. 2.9.31, and ISO 22412. Both techniques are referenced within the ICH Q4A framework for analytical method harmonisation. Regulatory submissions should specify which standard was followed and include method validation data.
Yes. Laser diffraction and DLS are complementary rather than competing techniques. A common strategy in pharmaceutical development is to use laser diffraction for bulk powder characterisation and in-process control of granulation or milling, while DLS is used for nanosized drug carriers, protein formulations, and stability monitoring. Using both techniques provides a more complete picture of the particle size landscape across different formulation stages.
Still have questions? Let PatSnap Eureka answer them for you.
Ask Eureka About Particle Size MethodsAccelerate Your Particle Size Characterisation R&D
Search global patents, literature, and regulatory filings on laser diffraction, DLS, and pharmaceutical particle analysis — all in one AI-powered platform.
References
- United States Pharmacopeia (USP) — USP <429> Light Diffraction Measurement of Particle Size
- ISO 13320:2020 — Particle Size Analysis: Laser Diffraction Methods (International Organization for Standardization)
- ISO 22412:2017 — Particle Size Analysis: Dynamic Light Scattering (International Organization for Standardization)
- ICH Q4A — Pharmacopoeial Harmonisation Framework (International Council for Harmonisation)
- EMA Reflection Paper on Nanotechnology-Based Medicinal Products for Human Use (European Medicines Agency)
- NIST — Stokes-Einstein Equation and Diffusion Coefficient Reference Data (National Institute of Standards and Technology)
- PatSnap — Innovation Intelligence Platform, 2B+ Global Patent and Literature Data Points
All analytical framework descriptions and regulatory references on this page are drawn from publicly available pharmacopoeial standards, ICH guidance documents, and regulatory agency publications cited above, supplemented by PatSnap's proprietary innovation intelligence platform.
PatSnap Eureka searches patents and research to answer instantly.